I’m a little surprised there’s not more discussion of the high level of dropouts in the apabetalone group vs the control (114 vs 69 discontinuations due to adverse events). No Hy’s law is good, but looks like nearly 10% of patients had elevated ALT, and liver issues caused more dropouts in the treatment group.

I’m not sure how strong an association there may be between liver function and MACE, but if there is an increased likelihood then it seems like the higher number of dropouts for this reason could skew the study results.

Why is the elevated ALT not considered a safety issue?

https://pbs.twimg.com/media/EJgloizWwAcBflx?format=jpg&name=large